Inspire Medical Systems (NYSE:INSP) Trading 6.6% Higher – Should You Buy?

Inspire Medical Systems, Inc. (NYSE:INSP)’s share price rose 6.6% during mid-day trading on Monday . The stock traded as high as $42.32 and last traded at $42.6960. Approximately 63,037 shares were traded during trading, a decline of 95% from the average daily volume of 1,229,793 shares. The stock had previously closed at $40.05.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on INSP shares. Weiss Ratings cut shares of Inspire Medical Systems from a “sell (d+)” rating to a “sell (d)” rating in a research report on Wednesday, May 6th. Oppenheimer reissued a “market perform” rating on shares of Inspire Medical Systems in a report on Thursday, May 7th. Wells Fargo & Company reduced their price objective on shares of Inspire Medical Systems from $70.00 to $56.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 5th. Morgan Stanley set a $60.00 target price on Inspire Medical Systems in a research report on Wednesday, February 18th. Finally, UBS Group set a $67.00 price target on Inspire Medical Systems in a report on Friday, February 13th. Four research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $85.00.

Inspire Medical Systems Price Performance

The company’s fifty day simple moving average is $53.40 and its 200-day simple moving average is $77.39. The firm has a market capitalization of $1.20 billion, a PE ratio of 9.30, a price-to-earnings-growth ratio of 4.14 and a beta of 0.83.

Inspire Medical Systems (NYSE:INSP) last issued its quarterly earnings data on Monday, May 4th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.28) by $0.38. Inspire Medical Systems had a return on equity of 10.35% and a net margin of 14.33%.The firm had revenue of $204.58 million during the quarter, compared to analyst estimates of $200.04 million. During the same quarter in the prior year, the business posted $0.10 EPS. The business’s revenue for the quarter was up 1.6% compared to the same quarter last year. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. As a group, equities research analysts anticipate that Inspire Medical Systems, Inc. will post 0.91 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Inspire Medical Systems

A number of large investors have recently modified their holdings of the business. CWM LLC boosted its stake in Inspire Medical Systems by 216.1% in the 4th quarter. CWM LLC now owns 354 shares of the company’s stock worth $33,000 after purchasing an additional 242 shares in the last quarter. Havemeyer Place LP acquired a new position in Inspire Medical Systems during the 4th quarter valued at approximately $39,000. V Square Quantitative Management LLC purchased a new position in shares of Inspire Medical Systems in the fourth quarter worth $40,000. Smartleaf Asset Management LLC lifted its stake in shares of Inspire Medical Systems by 84.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 449 shares of the company’s stock worth $42,000 after buying an additional 205 shares during the period. Finally, Larson Financial Group LLC lifted its stake in shares of Inspire Medical Systems by 21,266.7% during the third quarter. Larson Financial Group LLC now owns 641 shares of the company’s stock worth $48,000 after buying an additional 638 shares during the period. Hedge funds and other institutional investors own 94.91% of the company’s stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.